

We invite you to engage in an interactive nintely minute roundtable led by EverythingALS consortia of Pharma partners, sensor companies, neurologists, data scientists, regulators and patients to help advance the discovery and implementation of ALS digital biomarkers in clinical trials through our collaborative efforts.
Joining our participatory roundtable, you will be the first to learn about our latest study results on ALS digital biomarkers as well as have the opportunity to hear why major pharmaceutical companies have joined the consortium to partner in EverythingALS research, which will be expanded to include analyzing data from wearables and smartphones.
As always, we approach each roundtable to encourage out-of-the-box thinking, and to kick it off, we have an exciting agenda! Take a look below.
This is an invite only event.
Hosts & Speakers

Agenda
Friday June 25th, 2025
12:30 - 2:00 PM ET I 9:30 - 11:00 AM PT
10 minutes
10 minutes
10 minutes
20 minutes
10 minutes
10 minutes
Highlights and Announcements
Indu Navar, Founder & CEO, EverythingALS
Welcome the new Consortia members
Lars Ittner, MD. Founder and Chief Medical Officer, Celosia Therapeutics
Olga Uspenskaya, MD, PhD. Chief Medical Officer, VectorY Therapeutics
Keynote: "It broke my heart, because I loved what I do!”
Monica Martinez, Person Living with ALS
Listener Effort as a Marker of Dysarthria Progression in ALS.
FDA Drug Development Tool (DDT) CDER - Context of Use and Next Steps
Dr. James Berry, Chief, Division of ALS and MND, Mass General Brigham
Brendan O'Leary, Medical and Digital Health, Regulation, and Policy
Henk Schuring, Chief Regulatory and Commercialization Officer, Prilenia
Research Recognition
Research and Data Science Team, EverythingALS
Collaboration Highlights
Kelly Norel, PhD, Staff Research Scientist, Digital Health, IBM
Julian Peller, Head of Data Science, EverythingALS
END OPEN SESSION
CONSORTIA MEMBERS' BREAKOUT
1:40-2:00 PM ET
Closed session
Aug 10 & 11th Consortia Summit: Agenda Finalization